Dengue Vaccines

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 May 2015) | Viewed by 7173

Special Issue Editors

E-Mail Website
Guest Editor
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore

E-Mail Website
Co-Guest Editor
Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore
Interests: dengue virology and pathogenesis; flavivirus-host interactions; development of molecular correlates of vaccine and antiviral safety and efficacy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Dengue vaccine development has come a long way, but we are not there yet. The recently released results of the multi-centre Phase 3 efficacy trial in Asia for the live-attenuated, recombinant dengue fever vaccine (chimeric, with the 17D yellow fever virus as the backbone) have yet again shown that an optimal dengue vaccine remains a scientific challenge. The successful rollout of a vaccine that induces high levels of tetravalent protection may hinge on detailed understanding of dengue pathogenesis and immunity. Addressing the gaps in knowledge in these fields must thus be our top priority.

Immense progress has been made in the field of dengue virology and immunology in the past decade. The present issue on “Untangling the Complexity of Dengue Vaccine Development” will bring together primary data on clinical, virological, and immunological studies. Up-to-date summaries of pre-clinical and phase 1–3 trials will provide an indication of the current status of dengue vaccine development. Lastly, this issue will also include articles that address the economics and policies related to dengue vaccine introduction. We envisage that this Special Issue will serve as both an information resource as well as a timely alignment between primary research efforts and vaccine development strategies.

Prof. Dr. Annelies Wilder-Smith
Prof. Dr. Eng Eong Ooi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • dengue
  • live attenuated dengue vaccines
  • new generation dengue vaccines
  • inactivated dengue vaccines
  • immune correlate
  • human controlled infections
  • vaccine efficacy
  • antibody dependent immune enhancement
  • cellular immunity

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


230 KiB  
Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
by Indira S. Harahap-Carrillo, Ivonne Ceballos-Olvera and Jorge Reyes-del Valle
Vaccines 2015, 3(3), 503-518; - 3 Jul 2015
Cited by 18 | Viewed by 6710
Vaccines against dengue virus (DV) are commercially nonexistent. A subunit vaccination strategy may be of value, especially if a safe viral vector acts as biologically active adjuvant. In this paper, we focus on an immunoglobulin-like, independently folded domain III (DIII) from DV 2 [...] Read more.
Vaccines against dengue virus (DV) are commercially nonexistent. A subunit vaccination strategy may be of value, especially if a safe viral vector acts as biologically active adjuvant. In this paper, we focus on an immunoglobulin-like, independently folded domain III (DIII) from DV 2 envelope protein (E), which contains epitopes that elicits highly specific neutralizing antibodies. We modified the hepatitis B small surface antigen (HBsAg, S) in order to display DV 2 DIII on a virus-like particle (VLP), thus generating the hybrid antigen DIII-S. Two varieties of measles virus (MV) vectors were developed to express DIII-S. The first expresses the hybrid antigen from an additional transcription unit (ATU) and the second additionally expresses HBsAg from a separate ATU. We found that this second MV vectoring the hybrid VLPs displaying DIII-S on an unmodified HBsAg scaffold were immunogenic in MV-susceptible mice (HuCD46Ge-IFNarko), eliciting robust neutralizing responses (averages) against MV (1:1280 NT90), hepatitis B virus (787 mIU/mL), and DV2 (1:160 NT50) in all of the tested animals. Conversely, the MV vector expressing only DIII-S induced immunity against MV alone. In summary, DV2 neutralizing responses can be generated by displaying E DIII on a scaffold of HBsAg-based VLPs, vectored by MV. Full article
(This article belongs to the Special Issue Dengue Vaccines)
Show Figures

Graphical abstract

Back to TopTop